Response to Dual Crizotinib and Osimertinib Treatment in a Lung Cancer Patient with MET Amplification Detected by Liquid Biopsy Who Acquired Secondary Resistance to EGFR Tyrosine Kinase Inhibition.

J Thorac Oncol

Department of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York. Electronic address:

Published: September 2018

Download full-text PDF	Source
http://dx.doi.org/10.1016/j.jtho.2018.04.007	DOI Listing

Publication Analysis

response dual

dual crizotinib

crizotinib osimertinib

osimertinib treatment

treatment lung

lung cancer

cancer patient

patient met

met amplification

amplification detected

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!